Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
PMID 21609656
Survodutide (BI 456906) is a novel subcutaneous GCGR/GLP-1R dual agonist in development for the treatment of people with type 2 diabetes, obesity and non-alcoholic steatohepatitis (NASH)
Owing to its flexibility, this strategy can be implemented in both Boc- and Fmoc-based solid-phase peptide synthesis (SPPS), as well as in solution-phase peptide synthesis
Best practice & research
Unlike oral supplements, they bypass the digestive system so your body gets what it needs right away
US$ 23.59
US$ 29.29
:max_bytes(150000):strip_icc()/Health-GettyImages-2236560849-a1934f1e4c004a19835cb508d021388b.jpg)
US$ 21.00
US$ 23.77
